Oxytocin is the first-line uterotonic medication after dilation and curettage
For bleeding prophylaxis after D&C, administer intravenous oxytocin as the primary uterotonic agent to promote uterine contraction and reduce blood loss.
Evidence-Based Rationale
The most recent high-quality evidence from 2025 specifically evaluating hemorrhage prophylaxis during second-trimester dilation and evacuation procedures demonstrates that intravenous oxytocin decreases procedural blood loss 1. This systematic review of 3,857 patients found that oxytocin use resulted in decreased blood loss without differences in subsequent interventions needed to control bleeding 1.
Alternative Agents Based on Clinical Context
Paracervical Vasopressin
- Moderate-quality evidence shows paracervical vasopressin decreases blood loss, particularly at advanced gestational ages 1
- Consider this as an alternative or adjunct, especially for second-trimester procedures
Misoprostol
- Evidence remains unclear for bleeding prophylaxis specifically 1
- Studies were primarily designed to assess cervical dilation rather than hemorrhage prevention
- Overall low-quality evidence for this indication
Avoid Methylergonovine
- High-quality evidence shows methylergonovine actually increased blood loss at the time of procedure 1
- Should not be used as first-line prophylaxis
Dosing Considerations
Recent evidence supports using lower doses of oxytocin than historically employed, as the oxytocin receptor undergoes desensitization with higher concentrations and prolonged exposure 2. This is particularly relevant for D&C procedures where rapid uterine contraction is needed.
Second-Line Options if Bleeding Persists
If oxytocin proves inadequate, consider second-line uterotonics earlier than traditional practice:
- Carboprost (contraindicated in asthma)
- Ergometrine (contraindicated in hypertension)
- Misoprostol as rescue therapy
The choice depends on patient comorbidities 2.
Critical Pitfall to Avoid
Do not rely on methylergonovine as prophylaxis after D&C—the evidence shows it worsens rather than improves bleeding outcomes in this setting 1.